Avalo Therapeutics

AVTX · NASDAQ

$12.36+$0.77 (+6.64%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $11.59

AVTX analyst rating

BuyConsensus of 11 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy11
Hold0
Underperform0
Sell0

12-month price target · 13 analysts

Average $45.81 (+270.6% upside)

Low: $30.30
Now: $12.36
High: $63.00

Upgrades and downgrades

The latest rating actions, newest first

AVTX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Guggenheim	Aug 7, 2026	Maintains	Buy	$50.00 → $48.00	49%
HC Wainwright & Co.	Aug 7, 2026	Maintains	Buy	$35.00 → $30.00	32%
Leerink Partners	Jul 6, 2026	Initiates	Outperform	$38.00	25%
BTIG	Jun 16, 2026	Maintains	Buy	$58.00	34%
B of A Securities	Jun 12, 2026	Initiates	Buy	$35.00	36%
Citizens	May 14, 2026	Maintains	Market Outperform	$62.00 → $55.00	41%
Wedbush	May 14, 2026	Maintains	Outperform	$40.00 → $34.00	39%
Mizuho	May 14, 2026	Maintains	Outperform	$39.00 → $45.00	54%
HC Wainwright & Co.	May 14, 2026	Maintains	Buy	$40.00 → $35.00	32%
Piper Sandler	May 11, 2026	Maintains	Overweight	$48.00 → $60.00	37%

The case for and against

Updated Oct 14, 2026

Bull case

Avalo Therapeutics is attractive because abdakibart has generated positive Phase II LOTUS data in hidradenitis suppurativa, with about 42.5% to 45.2% HiSCR-75 and placebo-adjusted benefit near 17% to 19.4%, supporting the view that its anti-IL-1β biology is clinically de-risked. The company also has roughly $472 million in cash and investments as of May 31, which is expected to fund operations into 2029 and allows it to advance the registrational Phase III program without near-term financing pressure. Beyond abdakibart, the pipeline adds optionality through AVTX-010 and other assets, while the planned 1H27 Phase III initiation and 2H26 regulatory and readthrough catalysts provide a clear path to value creation.

Bear case

Avalo Therapeutics is a clinical-stage biotech with limited near-term revenue visibility, and its valuation remains highly dependent on abdakibart’s success despite meaningful execution risk across the pipeline. The 2Q26 financing lifted cash, cash equivalents, and investments to $472.2M from $82.0M and is expected to fund operations into 2029, but OpEx rose 50.8% Q/Q to $31.5M and net loss widened 85.2% Q/Q to $36.4M, underscoring continued cash burn. The bearish view is driven by the possibility of delays in clinical development, negative safety or efficacy readthrough versus competitor benchmarks, failure to achieve approval, slower commercial uptake, and long-term equity dilution risk.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.